Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013
AUTOR(ES)
Moraes, Camile de, Moraes, José Cássio de, Silva, Gabriela Drummond Marques da, Duarte, Elisabeth Carmen
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2017-04
RESUMO
BACKGROUND Meningococcal C conjugate (MenC) vaccine was introduced as part of the Brazilian National Immunisation Program in 2010 for children < 1 year of age. OBJECTIVES The study objective was to evaluate the impact of this vaccination strategy. METHODS An observational, mixed ecological and analytical study was conducted, based on time series panel data from surveillance records (2001-2013). FINDINGS A total of 37,538 of meningococcal disease cases were recorded during the study period. Of these, 19,997 were attributed to serogroup C. A decrease in meningococcal disease serogroup C (MDC) incidence among children aged < 1 year [65.2%; 95% confidence interval (CI): 20.5-84.7%] and 1-4 years (46.9%; 95%CI: 14.6-79.1%) were found in the three years following vaccination introduction. Vaccination impact on the reduction of MDC incidence varied from 83.7% (95%CI: 51.1-100.0%) in the Midwest region to 56.7% (95%CI: 37.4-76.0%) in the Northeast region. MAIN CONCLUSIONS Vaccination against MDC in Brazil had a positive impact on the population of children aged < 1 year, across all regions, and on the 1-4 year-old cohort. Nevertheless, in our view there is scope for improving the vaccination strategy adopted in Brazil.
Documentos Relacionados
- Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998–2007
- [PROVISIONAL] Birth defects in Brazil: Outcomes of a population-based study
- Autoimmune disease and risk for Parkinson disease: A population-based case-control study
- Tendência da hanseníase em menores de 15 anos em Mato Grosso (Brasil), 2001-2013
- The Oslo Health Study: The impact of self-selection in a large, population-based survey